Pancreatitis Trial, Recruiting NCT06041009 Sponsor: Qilu Hospital of Shandong University Condition: Pancreatitis
Back to Pancreatitis

Pancreatitis Trial, Recruiting

NCT06041009
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with pancreatic cancer
  • People who are considered high-risk for developing pancreatic cancer
  • People who have been diagnosed with certain non-cancerous or less aggressive pancreatic tumors, such as solid pseudopapillary tumors or neuroendocrine tumors of the pancreas
  • People who have other medical conditions that have caused their CA19-9 blood marker levels to be unusually high (CA19-9 is a protein sometimes linked to pancreatic cancer)
  • People who have no pancreatic disease and normal CA19-9 levels based on blood tests and imaging scans (these individuals would be part of a comparison group)

Who may not be able to join:

  • People who are under 18 years of age
  • People who are suspected of having a cancerous growth in the pancreas but have not yet received a confirmed diagnosis through imaging scans or tissue testing
  • People who have not signed the required consent form agreeing to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ning Zhong, MD, Qilu Hospital of Shandong University

Phone: 18560086106

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Qilu Hospital of Shandong University
Registry
ClinicalTrials.gov
Start date
5 May 2023
Est. completion
30 September 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov